Pramlintide


Synthetic amylin analog

A synthetic analog of the pancreatic peptide hormone amylin; used adjunctively with insulin in type 1 and type 2 diabetes for postprandial glucose control.

Abstract

Pramlintide (modified 37-amino-acid amide derived from amylin; CAS 151126-32-8; molecular weight 3949.4) is a synthetic analog of amylin (islet amyloid polypeptide), a pancreatic beta-cell peptide co-secreted with insulin. The native amylin is amyloidogenic; pramlintide substitutes proline for residues at positions 25, 28, and 29 to disrupt amyloid fibril formation while preserving receptor binding. Approved by the FDA in 2005 under the trade name Symlin. Mechanism: amylin receptor agonism produces three principal effects: slowed gastric emptying (delays glucose absorption), suppression of postprandial glucagon (reduces hepatic glucose output), and increased satiety (promotes voluntary caloric reduction). Approved as adjunct to mealtime insulin in type 1 and insulin-using type 2 diabetes; produces approximately 0.4 percent reduction in HbA1c and modest weight loss. Plasma half-life is approximately 50 minutes; subcutaneous administration before each major meal. Used as the canonical amylin analog in metabolic research.

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.


Browse all monographs

Previous monograph
Next monograph